Hovione Announces the Appointment of Colin Minchom, PhD, MRPharmS as Vice President, Particle Design Business Unit

Mar 12, 2012, 08:33 ET from Hovione

LOURES, Portugal, March 12, 2012 /PRNewswire/ --

Hovione today announced the appointment of Dr. Colin Minchom as Vice President of its Particle Design Business Unit. Dr. Minchom was most recently with Patheon where he held the position of Vice President, Pharmaceutical Development Services for North America.  Based in East Windsor, New Jersey, Dr. Minchom will report to Guy Villax, Hovione's Chief Executive Officer.

"We are very pleased to welcome Dr. Minchom to Hovione. He is an excellent addition to our management team in an area of critical importance to our customers. Dr. Minchom is responsible for innovating Hovione's Pharmaceutical Particle Design offerings to meet the development and commercial supply needs of the formulator with poorly bioavailable or otherwise challenging molecules," said Mr. Guy Villax.

"I look forward to building on what has been achieved by Hovione to date in its creation of solutions for customers needing Particle Design for improved bioavailability and also specialist delivery by non-oral routes," said Dr. Minchom.

Dr. Minchom's 29-year career includes extensive experience in the process, science and global regulation of drug development with emphasis on dosage forms and drug delivery. Prior to this role at Patheon Dr. Minchom was Head of Pharmaceutical Sciences at Cerebrus Ltd., a UK privately held pharmaceutical company and has also held positions of increasing scientific and management responsibility at Eli Lilly and E.R. Squibb in formulation and product development, project management and product management.

Dr. Minchom is chair of the American Association of Pharmaceutical Scientists (AAPS) 2012 Annual Meeting Planning Committee for Chicago. He also serves as a volunteer at the United States Pharmacopoeia (USP) as member of an Expert Committee addressing small molecules. Dr. Minchom was until recently an advisor at the Medical and Related Sciences Discovery District (MaRS) incubator in Toronto, Canada.

Trained as a pharmacist at the Leicester School of Pharmacy in the UK, he holds a PhD in Industrial Pharmacy from the University of Wales College of Cardiff.

About Hovione. Hovione is a global company with over 50 years' experience in Active Pharmaceutical Ingredient and Intermediate Drug Product development and compliant manufacture. With four FDA inspected sites in the U.S., China, Ireland, and Portugal, the company focuses on the most demanding customers, in the most regulated markets. Hovione offers integrated API, particle design and formulation development and manufacturing. In the inhalation area, Hovione is the only independent company offering such a broad range of services.

For more information about Hovione, please visit http://www.hovione.com or contact Marketing & Communication,  Isabel Pina, +351-21-982-9362, e-mail: ipina@hovione.com. To read the Press click here.

SOURCE Hovione